详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Efficacy and Safety of Nivolumab Therapy for Advanced NSCLC in the Expanded Access Named Patient Program in Taiwan

文献详情

资源类型：

作者：

机构： [1]Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; [2]Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan; [3]Sun Yat Sen Canc Ctr, Dept Med Oncol, Taipei, Taiwan; [4]China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care, Taichung, Taiwan; [5]Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [6]Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan; [7]Buddhist Dalin Tzu Chi Hosp, Dept Internal Med, Chiayi, Taiwan; [8]Chi Mei Med Ctr, Liouying, Taiwan; [9]Chi Mei Med Ctr, Dept Hematooncol, Tainan, Taiwan; [10]Chiayi Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Chiayi, Taiwan; [11]Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Hematol Oncol, Taipei, Taiwan; [12]Hualien Tzu Chi Hosp, Buddhist Tzu Chi Fdn, Dept Internal Med, Chest Sect, Hualien, Taiwan; [13]I Shou Univ, E Da Hosp, Dept Internal Med, Kaohsiung, Taiwan; [14]Chung Shan Med Univ Hosp, Div Med Oncol & Chest Med, Taichung, Taiwan; [15]Chung Shan Med Univ Hosp, Dept Internal Med, Div Chest, Taichung, Taiwan; [16]Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Kaohsiung, Taiwan; [17]Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan

出处：

DOI：

ISSN：

关键词： Expanded Access Program non-small cell lung cancer Nivolumab

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

第一作者：

第一作者机构： [1]Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan;

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia [2]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [3]Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. [4]Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)(Open Access) [5]KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review [6]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [7]RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells [8]Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression [9]Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer [10]A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery